<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Hypertension v3.0 MeG-CLS-010</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
<script src="myScript.js"></script><link rel="stylesheet" href="myStyle.css"></head>
<body> <div w3-include-html="panel.html"></div> <script> includeHTML(); </script>
<article class="markdown-body">
<h1 id="hypertension">Hypertension</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>Hypertension means elevated (arterial) blood pressure. It is the leading modifiable risk factor for death and disability worldwide. Starting from 115/75 mmHg, every 20 mmHg increase in systolic blood pressure or 10 mmHg rise in diastolic blood pressure doubles the risk of death from cardiovascular disease.</p>
<p>Between 18 to 32% of adults in The Gambia are hypertensive. Over 90% of hypertension is of unknown cause (essential/primary/ idiopathic) with risk factors including increasing age, male sex, Black race and family history of hypertension. Most cases of secondary hypertension result from renal disease.</p>
<h3 id="target-users">Target users</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
</ul>
<h3 id="target-area-of-use">Target area of use </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Gate clinic</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
</ul>
<h3 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h3>
<p>This guideline addresses the diagnosis and treatment of hypertension in the CSD.</p>
<p>The evaluation of patients with hypertension is aimed at identifying possible underlying causes, assessing overall cardiovascular risk and detecting complications.</p>
<p>Patients seen at the Gate Clinic with blood pressure above 140/90 mmHg should be referred to the outpatient department if there is markedly or persistently raised blood pressure, hyperglycaemia, proteinuria or alarming symptoms.</p>
<p>Drug therapy combined with lifestyle measures is recommended to achieve a target blood pressure of less than 140/90 mmHg. Choice of drugs depends on stage of hypertension at presentation, compelling indications and presence of comorbid conditions. Once-daily medications are preferred to improve adherence to drug therapy. Drug therapy should be adjusted until target blood pressure is reached provided adherence is satisfactory. Once blood pressure control is achieved, do not reduce medication doses unless side-effects occur.</p>
<p>Patients seen in Fajara should be discharged to local care when they are stable. Patients in Keneba should continue care at their Gate Clinic.</p>
<p>This guideline has been updated to address differences between Fajara and Keneba.</p>
<h3 id="limitations">Limitations </h3>
<h2 id="this-guideline-does-not-address-the-emergency-management-of-acute-hypertensive-emergencies.">This guideline does not address the emergency management of acute hypertensive emergencies.<br />
</h2>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<p>Hypertension is generally accepted as a systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg or use of antihypertensive medication prescribed by a qualified clinician.</p>
<h3 id="symptoms">Symptoms:</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Uncomplicated essential hypertension is usually asymptomatic.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Secondary hypertension may present with symptoms of underlying disease condition.</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Facial puffiness, nocturia, or passage of dark or frothy urine is suggestive of renal disease</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Excessive sweating, palpitations and heat intolerance suggests hyperthyroidism</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Episodes of palpitations, dizziness, headache and sweating may occur in phaeochromocytoma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Suspect secondary hypertension in patients newly diagnosed with hypertension who are younger than 30 years.</p>
</div></li>
</ul></li>
<li><div data-custom-style="List Paragraph">
<p>Features of some common complications:</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Dyspnea on exertion, difficulty lying flat (orthopnea), bilateral leg swelling in heart failure</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Slurred speech, limb weakness in stroke</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Headache, abnormal behavior, altered consciousness, seizures in hypertensive encephalopathy</p>
</div></li>
</ul></li>
</ul>
<h3 id="signs">Signs:</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>In earlier stages, no other presenting signs apart from raised blood pressure in essential hypertension</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Secondary hypertension may present with signs of the underlying condition</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hypertension may also present with signs of complications such as stroke, encephalopathy, renal failure or heart failure.</p>
</div></li>
</ul>
<h2 id="examination-findings">Examination findings</h2>
<p>Please note that all nurses and doctors must ensure that the sphygmomanometers are sent off to Biomed periodically (every 6 months and in batches) so that they can be maintained and recalibrated according to manufacturer’s instructions.</p>
<p>When checking BP for a patient for the first time, measure both arms. If the difference in readings in both arms is more than 15 mmHg, please repeat the measurements. If the difference in readings between both arms remains more than 15 mm Hg on the second measurement, measure subsequent blood pressures in the arm with the higher reading.</p>
<p>If blood pressure measured in clinic is 140/90 mmHg or higher, take a second measurement during the consultation. If the second measurement is substantially different from the first, take a third measurement. Record the lower of the last two measurements as the clinic blood pressure.</p>
<h3 id="important-things-to-look-for-in-opd">Important things to look for in OPD: </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Features of long-standing hypertension: thickened arterial walls, heaving apex beat, loud aortic component of second heart sound, retinal changes on fundoscopy.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Radiofemoral delay: Coarctation of the aorta</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Renal bruit: Renal artery stenosis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ballotable kidneys: Polycystic kidney disease</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pallor, peripheral oedema, facial oedema: Chronic kidney disease</p>
</div></li>
</ul>
<h2 id="differential-diagnoses">Differential diagnoses</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Renal disease</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Vascular disorders</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Renal artery stenosis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Coarctation of the aorta</p>
</div></li>
</ul></li>
<li><div data-custom-style="List Paragraph">
<p>Endocrine disorders</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Hypothyroidism</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Hyperthyroidism</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Phaeochromocytoma</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Adrenal hypersecretion (Cushing syndrome, Conn syndrome)</p>
</div></li>
</ul></li>
<li><div data-custom-style="List Paragraph">
<p>Drugs:</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Steroids (including oral contraceptive pills)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Non-steroidal anti-inflammatory drugs (NSAIDs)</p>
</div></li>
</ul></li>
<li><div data-custom-style="List Paragraph">
<p>Hypertensive disorders of pregnancy</p>
</div></li>
</ul>
<h2 id="investigations">Investigations</h2>
<h3 id="to-exclude-a-secondary-cause">To exclude a secondary cause </h3>
<p>For all patients under 30 years and others where there are signs to suggest another problem:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Urinalysis</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Proteinuria of 2+ or more suggests renal cause</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Haematuria may indicate nephritic syndrome</p>
</div></li>
</ul></li>
<li><div data-custom-style="List Paragraph">
<p>Serum Electrolytes, Urea &amp; Creatinine</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Elevated creatinine suggests renal involvement</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Derangements in potassium and bicarbonate may point to an adrenal problem</p>
</div></li>
</ul></li>
<li><div data-custom-style="List Paragraph">
<p>Full blood count</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Chronic kidney disease causes anaemia (microcytic or normocytic)</p>
</div></li>
</ul></li>
</ul>
<p><strong><span class="underline">To assess other important cardiovascular risk factors</span></strong></p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Fasting plasma glucose</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Fasting Serum Cholesterol (total and HDL only) – these should only be done if the patient does not already have a history of ischaemic heart disease or stroke. For such patients – estimate their cardiovascular risk using QRISK2 <a href="https://qrisk.org/2017/"><span data-custom-style="Hyperlink">https://qrisk.org/2017/</span></a></p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>If the risk is &gt; 10%, do not check the cholesterol, but advise the patient to start taking a statin anyway.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If the risk is &lt; 5%, they will not need to take a statin whatever their cholesterol level.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Only check the cholesterol for those patients with risk of 5-10%, then recalculate the risk once the result is available and recommend statins for those with a risk of 10% or more.</p>
</div></li>
</ul></li>
</ul>
<h3 id="to-detect-subclinical-complications">To detect subclinical complications</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>ECG</p>
</div></li>
</ul>
<p><strong><span class="underline">Management in Gate Clinic</span></strong></p>
<h2 id="at-the-first-visit-if-the-bp-is-14090-request-urine-dipstick-and-test-blood-glucose.">At the first visit if the BP is &gt; 140/90, request urine dipstick and test blood glucose.</h2>
<p>Refer to a doctor if:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>BP is greater than 180 mmHg (systolic) or 110 mmHg (diastolic)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>protein in the urine</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>blood glucose is raised (fasting &gt; 6.9 mmol/l, random &gt; 11.1 mmol/l)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>any complaints of shortness of breath, chest pain, severe headaches or visual disturbance.</p>
</div></li>
</ul>
<p>Otherwise, offer lifestyle modification advise to the patient as below:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Reduce the salt in their diet</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Lose weight if they are overweight</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Increase their regular exercise.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Increase intake of fruits, vegetables and nuts</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Reduce coffee intake</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Stop smoking and limit alcohol (if applicable)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ask them to return in 1-2 days.</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Repeat BP at the return visit. If it is greater than 140/90 mmHg on a second occasion, refer to the doctor.</p>
</div></li>
</ul></li>
</ul>
<h2 id="management-in-opd">Management in OPD</h2>
<p>The target blood pressure for treating hypertension is a systolic blood pressure of 140mmHg <strong>and</strong> a diastolic blood pressure of 90 mmHg. Drugs given once daily are preferred to improve adherence to treatment. Counsel patients adequately on the benefits of their treatment, side-effects and the risks of non-adherence. Remind them of the importance of avoiding salt intake and emphasise the need for life-long therapy.</p>
<p>Generally, for patients with systolic blood pressure less than 160 mmHg <strong>and</strong> diastolic blood pressure less than 100 mmHg, it is preferable to start with a <strong>single drug</strong>.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<blockquote>
<p>If the patients is not diabetic and has no signs of kidney disease, start with a thiazide at low dose (Bendroflumethiazide 2.5 mg OD)</p>
</blockquote>
</div></li>
<li><div data-custom-style="List Paragraph">
<blockquote>
<p>If the patient is diabetic without signs of kidney disease, start with a calcium channel blocker at low dose (Amlodipine 5 mg OD)</p>
</blockquote>
</div></li>
<li><div data-custom-style="List Paragraph">
<blockquote>
<p>If the patient has features of chronic kidney disease, place them on an ACE inhibitor (usually Enalapril 2.5 mg OD) at the lowest effective dose after excluding contraindications.</p>
</blockquote>
</div></li>
</ul>
<p>In black Africans, Angiotensin Receptor Blockers (ARBs) is preferred to ACEi (usual Losartan starting dose is 50mg OD), but this is not available at this clinic.</p>
<p>If blood pressure is still &gt;140/90 mmHg at subsequent clinic visits:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Enquire about adherence to drug therapy and lifestyle changes (lifestyle issues listed under gate clinic treatment) . Patients should be encouraged to bring their leftover/empty medication containers on clinic visits</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If adherence appears satisfactory, increase the dose of the medication gradually with each clinic visit until target blood pressure is reached or maximum dose of the drug is achieved.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If blood pressure is not at target despite maximum dose of the drug, add a second antihypertensive from a different class to the patient’s treatment (see flow chart below).</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Gradually increase this second drug until target blood pressure is reached or maximum dose of the drug is achieved.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Do not reduce drug doses after target blood pressure is attained unless patient has symptoms and signs of hypotension.</p>
</div></li>
</ul>
<p>For patients who present initially with systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg, or patients whose blood pressure is not at target despite maximum dose of the drug, <strong>combination therapy</strong> is recommended.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>For patients without diabetes mellitus or kidney disease, start with a combination of a calcium channel blocker and a thiazide diuretic (Amlodipine 5 mg OD and Bendroflumethiazide 2.5 mg OD).</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>For patients with diabetes mellitus, start with a calcium channel blocker and an ACE inhibitor.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>For patients with kidney disease, place the patient on a combination of an ACE inhibitor with either a calcium channel blocker or a thiazide diuretic.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Gradually increase the doses of individual drugs at subsequent clinic visits until either target blood pressure is achieved or the maximum doses of <strong>both</strong> drugs are reached.</p>
</div></li>
</ul>
<p>Compelling indications are special conditions in which particular classes of hypertension drugs must be prescribed.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Pregnancy: alpha-methyldopa, nifedipine, labetalol or hydralazine</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Chronic kidney disease: ACE inhibitors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Heart failure: ACE inhibitors + spironolactone + diuretics (+ beta blocker when stable)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Previous stroke: ACE inhibitors or thiazide diuretic.</p>
</div></li>
</ul>
<p>Patients who do not have adequate control after following this flow chart:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Those who are not at target despite a combination of two drugs at maximum doses should have a third drug from an unused class added (ACEI +CCB +Thiazide).</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Those who remain uncontrolled at maximal doses of three drugs should be re-evaluated for secondary hypertension. A fourth drug (spironolactone or a beta blocker) can be added. In deciding which of the above to use, check potassium level of the patient: If it is 4.5 mmol/L or less, use low dose spironolactone at 25mg. Beta blockers preferred in those with potassium level of 4.5 mmol/L or more. Specialist advice (cardiology in Gambia /nephrology in Dakar) necessary if there is still no BP control after this.</p>
</div></li>
</ul>
<p><strong><span class="underline">Considerations for individual drugs</span></strong></p>
<table>
<thead>
<tr class="header">
<th><strong>Drug group</strong></th>
<th><strong>Indications</strong></th>
<th><strong>Contraindications and monitoring</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><p><strong>Thiazides</strong></p>
<p><em>Bendroflumethiazide 2.5 mg OD</em></p></td>
<td><p>First line if no DM or heart failure.</p>
<p>Add to ACEi / CCB to improve control.</p>
<p>Do not increase dose – it increases the side effects without improving effectiveness.</p></td>
<td>Ensure that patients are counseled regarding risks of diuretic use and necessity to omit medications when having an intercurrent diarrhoeal illness.</td>
</tr>
<tr class="even">
<td><p><strong>Calcium channel blockers (CCB)</strong></p>
<p><em>Amlodipine 5-10 mg OD</em></p></td>
<td><p>First line for co-existing DM.</p>
<p>Second line in pregnancy (but use nifedipine not amlodipine).</p></td>
<td></td>
</tr>
<tr class="odd">
<td><p><strong>ACE inhibitors (ACEi)</strong></p>
<p><em>Enalapril 2.5-10 mg OD or BD</em></p></td>
<td>First line for co-existing heart failure.</td>
<td><p>Check K and Creatinine one month after start of treatment and stop if creatinine rises by &gt; 30%.</p>
<p>ACE inhibitors can cause a chronic dry cough. All patients should watch out for angioedema.</p>
<p>Female patients on ACE inhibitors should be counseled on the danger of using them in pregnancy.</p></td>
</tr>
<tr class="even">
<td><p><strong>Spironolactone</strong></p>
<p><em>25-100 mg OD</em></p></td>
<td>Fourth line for patients with uncontrolled BP despite being on 3 other medications.</td>
<td>Avoid if serum potassium is &gt; 4.5 mmol/l.</td>
</tr>
<tr class="odd">
<td><p><strong>Beta blockers</strong></p>
<p><em>Bisoprolol 1.25-10 mg OD</em></p></td>
<td>Fourth line for stable heart failure or for patients with uncontrolled BP despite being on 3 other medications.</td>
<td></td>
</tr>
<tr class="even">
<td><p><strong>Methyldopa</strong></p>
<p>250 mg BD – 500 mg TDS</p></td>
<td>First line for pregnancy.</td>
<td></td>
</tr>
</tbody>
</table>
<p><strong>For patients seen at Fajara, discharge to local care once stable on medication.<br />
For patients seen at Keneba, continue care at the Gate Clinic once stable on medication.</strong></p>
<p>Recommend patient remains on medication and has annual blood tests.</p>
<p><strong><span class="underline"><br />
</span></strong></p>
<p><strong><span class="underline">Key Issues for Nursing care</span></strong></p>
<p>How to measure blood pressure correctly:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>The patient should be relaxed, comfortably seated with back supported, legs uncrossed and measured arm supported at heart level.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Radial or brachial pulse should be assessed for rhythm<strong>.</strong></p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If irregular, do not use the automatic blood pressure machine. Use a manual sphygmomanometer instead.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>An appropriate cuff size should be selected and applied mid-arm (about 2 cm above the elbow)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>The patient should not speak during blood pressure measurement.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Measure the blood pressure in both arms. If the difference is more than 20 mmHg between both arms, document the arm with higher reading and use this arm for all future measurements in the patient.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If the blood pressure reading is higher than 140/90 mmHg, repeat the measurement. If second measurement is significantly different, take a third reading and keep the lower of the last two values.</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p>Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH Jr et al. Management of High Blood Pressure in Blacks: An Update of the International Society on Hypertension in Blacks Consensus Statement. Hypertension. 2010;56:780-800.</p>
<p>National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE; 2011. Available from: <a href="http://www.nice.org.uk/guidance/cg127/chapter/1-Guidance"><span data-custom-style="Hyperlink">www.nice.org.uk/guidance/cg127/chapter/1-Guidance</span></a></p>
<p>National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE; 2020. Available from: <a href="http://www.nice.org.uk/guidance/cg127/chapter/1-Guidance"><span data-custom-style="Hyperlink">www.nice.org.uk/guidance/</span></a>ng136</p>
<p>James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J.2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).JAMA. 2014 Feb 5;311(5):507-20. doi: 10.1001/jama.2013.284427.</p>
<p>Armstrong C; Joint National Committee.JNC8 guidelines for the management of hypertension in adults.Am Fam Physician. 2014 Oct 1;90(7):503-4.</p>
<p>Williams SK, Ravenell J, Seyedali S, Nayef S, Ogedegbe G. Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines. Prog Cardiovasc Dis. 2016 Nov-Dec; 59(3): 282–288.</p>
<p>World Health Organization (WHO). Raised blood pressure. Geneva: WHO; 2018. Available from: <a href="http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/"><span data-custom-style="Hyperlink">http://www.who.int/gho/ncd/risk_factors/blood_pressure_prevalence_text/en/</span></a></p>
<p>Alexander MR. Hypertension. Medscape; 2018. Available from: <a href="https://emedicine.medscape.com/article/241381"><span data-custom-style="Hyperlink">https://emedicine.medscape.com/article/241381</span></a></p>
<p><span data-custom-style="Hyperlink"><br />
</span></p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Fatai Momodu Akemokwe</th>
<th>Date: 22 May 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Karen Forrest</td>
<td>Date: 25 June 2018</td>
</tr>
<tr class="even">
<td><strong>Reviewed by:</strong></td>
<td>Name: Babatunde Awokola</td>
<td>Date: 24 June 2020</td>
</tr>
<tr class="odd">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="even">
<td>1.0</td>
<td>New document</td>
<td></td>
</tr>
<tr class="odd">
<td>2.0</td>
<td>Rewritten on new template and to address differences between Fajara and Keneba</td>
<td>31 July 2020</td>
</tr>
<tr class="even">
<td>2.1</td>
<td>Executive summary added</td>
<td>31 July 2020</td>
</tr>
<tr class="odd">
<td>3.0</td>
<td>Amendments have been made to examination findings, management in gate clinic, management in OPD. Reference list has been updated with NICE guidelines 2020</td>
<td>01 November 2022</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
